Mahutte Neal G, Matalliotakis Ioannis M, Goumenou Anastasia G, Koumantakis Georgios E, Vassiliadis Simon, Arici Aydin
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06520-8063, USA.
Fertil Steril. 2004 Jul;82(1):97-101. doi: 10.1016/j.fertnstert.2003.11.044.
To quantify levels of macrophage migration inhibitory factor (MIF) in the peritoneal fluid (PF) of women with endometriosis, and to correlate these levels with the extent of disease.
Controlled clinical study.
Academic medical center.
PATIENT(S): Peritoneal fluid samples were collected during laparoscopic surgery in 60 women with endometriosis and 16 controls undergoing tubal ligation; 52 of the women with endometriosis had received no hormonal treatment in the 6 months prior to surgery, while 8 were using gonadotropin-releasing hormone (GnRH) agonists.
MAIN OUTCOME MEASURE(S): Peritoneal fluid migration inhibitory factor (PF MIF) levels.
RESULT(S): Women with endometriosis had significantly higher PF MIF levels (10.8 +/- 0.9 ng/mL) than controls (3.0 +/- 0.7 ng/mL). However, no correlation existed between MIF levels and the stage of disease (r = 0.05) or the depth of endometriotic invasion (r = 0.08). Moreover, treatment with a GnRH agonist did not suppress PF MIF levels. Peritoneal fluid MIF levels did not vary significantly between the proliferative and secretory phases of the cycle, and did not distinguish women with endometriosis-associated infertility from women with endometriosis-associated pain.
CONCLUSION(S): Peritoneal fluid migration inhibitory factor levels are markedly elevated in women with endometriosis but are independent of the extent of disease.
量化子宫内膜异位症患者腹腔液中巨噬细胞移动抑制因子(MIF)的水平,并将这些水平与疾病程度相关联。
对照临床研究。
学术医疗中心。
在腹腔镜手术期间收集了60例子宫内膜异位症患者和16例接受输卵管结扎的对照者的腹腔液样本;60例子宫内膜异位症患者中有52例在手术前6个月未接受激素治疗,而8例正在使用促性腺激素释放激素(GnRH)激动剂。
腹腔液移动抑制因子(PF MIF)水平。
子宫内膜异位症患者的PF MIF水平(10.8±0.9 ng/mL)显著高于对照组(3.0±0.7 ng/mL)。然而,MIF水平与疾病分期(r = 0.05)或子宫内膜异位症侵袭深度(r = 0.08)之间无相关性。此外,GnRH激动剂治疗并未抑制PF MIF水平。腹腔液MIF水平在月经周期的增殖期和分泌期之间无显著差异,也无法区分子宫内膜异位症相关不孕症患者和子宫内膜异位症相关疼痛患者。
子宫内膜异位症患者腹腔液移动抑制因子水平显著升高,但与疾病程度无关。